Article Sidebar
Published:
Jun 4, 2018Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of combination of parenteral edaravone and nimodipine on ischemic cerebral injury following cerebral hemorrhage
Abstract
Purpose: To study the clinical effects of parenteral edaravone when combined with nimodipine for the treatment of ischemic cerebral injury following cerebral hemorrhage, and its influence on D-dimer, brain natriuretic peptide (BNP) and transcription factor kB (NF-kB) levels.
Methods: A total of 102 cases of ischemic cerebral injury after cerebral hemorrhage seen in 215 Hospital of Nuclear Industry in Shanxi, China from January, 2016 to January, 2017 were included in this study. They were randomly divided into two groups, viz, fifty-two cases in control group and fifty cases in observation group. Control group received nimodipine, while the observation group was given edaravone. Before and after treatment, the two groups’ NIHSS scores were compared. Adverse reactions were recorded, and clinical effectiveness was evaluated. Enzyme-linked immunosorbent assay (ELISA) was used to determin thee levels of serum D-dimmer, BNP and NF-kB in the two groups.
Results: Before treatment, the two groups’ NIHSS scores did not show significant differences (p > 0.05). However, after treatment, the observation group’s NIHSS score was significantly lower than that of the control group (p < 0.05). Total effectiveness in the observation and control groups were 98.0 and 80.8 %, respectively. Clinical effectiveness in patients in the observation group was significantly better than that of the control group (p < 0.05). Before treatment, D-dimmer, BNP and NF-kB levels of patients in the two groups showed no significant difference (p > 0.05). However, compared with the control group, D-dimmer, BNP and NF-kB levels in the observation group post-treatment decreased significantly (p < 0.05).
Conclusion: These results suggest that the combination of parenteral edaravone and nimodipine has relatively high efficiency and safety, mitigates cerebral ischemia and cerebral edema, and controls inflammatory reactions. Thus, its potentials in this regard requires further investigation.
Keywords: Edaravone, Nimodipine, Cerebral ischemia, Ischemic cerebral injury
